CLIAMS:CLAIMS
We claim:
1. A medical product for dressing wounds, the medical product comprising:
a substrate comprising a first part, a second part and an intermediate part, wherein the intermediate part is in between the first part and the second part, wherein the density of the intermediate part is lesser than the density of the first part and the second part; and
an antimicrobial agent, wherein the antimicrobial agent is Quaternary Ammonium Salt, wherein the antimicrobial agent is received by the substrate, thereby exposing the antimicrobial agent to an wound dressed using the medical product.
2. The medical product according to claim 1, wherein the antimicrobial agent is covalently bonded to the substrate.
3. The medical product according to claim 2, wherein the antimicrobial agent is covalently bonded to at least the second part and the intermediate part of the substrate.
4. The medical product according to claim 1, wherein the antimicrobial agent is 1-Tetradecanaminium, N,N-dimethyl-N-[3-(trimethoxysilyl)propyl]-, chloride.
5. The medical product according to claim 1, wherein the density of the first part is in the range of 20 Course per Inch to 60 Course per Inch, and 20 Wales per Inch to 60 Wales per Inch.
6. The medical product according to claim 1, wherein the thickness of the first part is in the range of 2.4 Micron to 7.0 Micron.
7. The medical product according to claim 1, wherein the density of the second part is in the range of 20 Course per Inch to 60 Course per Inch, and 20 Wales per Inch to 60 Wales per Inch.
8. The medical product according to claim 1, wherein the thickness of the second part is in the range of 2.4 micron to 7.0 micron.
9. The medical product according to claim 1, wherein the density of the intermediate part is in the range of 20 Piles Course per Inch to 70 Piles Course per Inch, and 30 Piles Wales per Inch to 50 Piles Wales per Inch.
10. The medical product according to claim 1, wherein the thickness of the intermediate part is in the range of 2 mm to 12 mm.
11. The medical product according to claim 1, wherein the substrate is made using a material comprising Polyethelne Teraphtahlate.
12. The medical product according to claim 1, wherein the substrate is made using a material comprising Polyethelne Teraphtahlate and Polyurethane.
13. The medical product according to claim 1, wherein the substrate is made using one or combination of material selected from a group consisting of fibre, filament, yarn, fabric, synthetic fiber, natural fiber, polyester, acrylic, polyamide, polyolefin, polyaramid, polyurethane, regenerated cellulose, poly acylonitriles, polytriphenylene terephthalate, polybutylene terephthalate, polylactic acid, aramides, metaramides, nylon 6, nylon 6,6, polypropylene, polyethylene, poly-p-phenyleneteraphthalamid, poly-m-phenyleneteraphthalamid, wool, cotton, flax, rayon, jute and linen.
14. The medical product according to claim 1, wherein the medical product comprises 80% to 90% Polyethelne Teraphtahlate by weight, 5% to 20% Polyurethane by weight and 0.5% to 1% antimicrobial agent by weight.
15. A medical product as herein above described in the specification with reference to figures. ,TagSPECI:F O R M 2

THE PATENTS ACT, 1970
(39 of 1970)
COMPLETE SPECIFICATION
(See section 10; rule 13)

1. TITLE OF THE INVENTION

MEDICAL PRODUCT FOR DRESSING WOUNDS

2. APPLICANT
A. Name: SHAKTHI KNITTING LIMITED
b. Nationality: an Indian company
c. Address: 3/606 C, Nochipalayam Road, Veerapandi Post, Tirupur, 641605, India

Complete specification:
The following specification particularly describes the invention and the manner in which it is to be performed.

BACKGROUND
Field
[001] In general, the subject matter relates to the field of medical textiles. More particularly but not exclusively, to a medical product used for dressing wounds.
Discussion of related field
[002] It is well known that exudate from wound provides nutrient to pathogens present in the wound, thereby facilitating their growth. In order to prevent growth of pathogens in the wound, medical products, such as, bandages, dressing material have been used to dress wounds, since time immemorial. Such medical products, when applied over the wound, absorb exudate from the wound.
[003] It has been observed that, such conventional medical products along with absorbing exudate also enable the property of limiting pathogen growth by using antimicrobial agent. One such antimicrobial agent is silver salt, which is coated over a substrate of the medical product. However, it has been observed that applying of such an antimicrobial agent over the substrate, results in leaching of the antimicrobial agent. Leaching of the antimicrobial agent interferes in the normal wound healing process. Further, leaching of the antimicrobial agent on the wound make the pathogens in the wound more resistant to the silver, thereby facilitating evolution of superburgs. These superburgs are significantly resistant to silver particles or normal drugs that are meant to kill the pathogens. Hence, such conventional medical products will have to be replaced frequently to avoid infection of the wound.
[004] It has also been observed that, such conventional medical products have a 2 dimensional structure. Such structures are provided essentially to have a coating of antimicrobial agent over one of its surfaces, and to prevent pathogens present in the air from entering the wound. In an effort to prevent pathogens present in the air from entering the wound, the medical product also prevents adequate air circulation. However, it is well know that oxygen supply to the tissues of the wounds helps in improved blood circulation, thereby resulting in faster healing.
[005] It has been further observed that such 2 dimensional structures have limited ability to absorb exudate, thereby requiring frequent replacement of the said conventional medical products. Furthermore, most of the conventional dressing products have limited or no pathogen killing properties, thereby necessitating frequent replacement of the dressing product. Delay in replacing the dressing product facilitates multiplication and growth of pathogens in the exudate of the wound. Such multiplication and growth of pathogens exposes the person wearing the dressing product to higher risk of sever wound infections.
[006] It shall be noted that, prior art, for example, US patent 8333743 granted to William, et al, discloses usage of a non-leaching antimicrobial agent. However, bandage material disclosed in the instant patent still suffers from some of the drawbacks discussed previously.
[007] In light of the foregoing discussion, there is a need for an improved medical product for dressing wounds.

STATEMENT OF INVENTION
[008] According, the invention provides a medical product for dressing wounds. The medical product comprises a substrate comprising a first part, a second part and an intermediate part, wherein the intermediate part is in between the first part and the second part, wherein the density of the intermediate part is lesser than the density of the first part and the second part; and an antimicrobial agent, wherein the antimicrobial agent is Quaternary Ammonium Salt, wherein the antimicrobial agent is received by the substrate, thereby exposing the antimicrobial agent to an wound dressed using the medical product
.

BRIEF DESCRIPTION OF DRAWINGS
[009] Embodiments are illustrated by way of example and not limitation in the Figures of the accompanying drawings, in which like references indicate similar elements and in which:
[0010] FIG. 1 illustrates an medical product 100 for dressing wounds, in accordance with an embodiment;
[0011] FIG. 2 is an exemplary illustration of a Quaternary Ammonium Salt, in accordance with an embodiment;
[0012] FIG. 3a illustrates a pathogen being drawn towards a positively charged Nitrogen, in accordance with an embodiment;
[0013] FIG. 3b illustrates rupturing a cell membrane of a pathogen, in accordance with an embodiment; and
[0014] FIG. 4 is an exemplary illustration of the medical product 100 applied over skin 404, in accordance with an embodiment.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

I. OVERVIEW
II. FIRST EXEMPLARY MEDICAL PRODUCT FOR DRESSING WOUNDS
III. EXEMPLARY ILLUSTRATION OF FUNCTIONING OF QAS
IV. EXEMPLARY ILLUSTRATION OF FUNCTIONING OF THE MEDICAL PRODUCT
V. EXEMPLARY USE OF THE MEDICAL PRODUCT
VI. CONCLUSION

I. OVERVIEW

[0015] Embodiments relates to the subject matter in the field of medical textiles. More particularly but not exclusively, to a medical product used for dressing wounds.
[0016] In an embodiment, a substrate is coated with an antimicrobial agent. The substrate includes three parts, namely a first part, an intermediate part and a second part. The intermediate part is between the first and the second part of the substrate. Further, intermediate part is relatively less dense compared to the first and the second part. Furthermore, an antimicrobial agent is received by the substrate, such that a wound is exposed to the antimicrobial agent when the medical product is used to dress the wound.
[0017] This three part substrate enables supply of oxygen to the wound. Further, the antimicrobial agent acts as a barrier against the entry of pathogens from the environment and also kills microbes present in the vicinity of the wound. It shall be noted that the antimicrobial agent is covalently bonded to the substrate and has non-leaching property.
[0018] The following detailed description includes references to the accompanying drawings, which form part of the detailed description. The drawings show illustrations in accordance with example embodiments. These example embodiments are described in enough detail to enable those skilled in the art to practice the present subject matter. However, it will be apparent to one of ordinary skill in the art that the present invention may be practiced without these specific details. In other instances, well-known methods, procedures, components, circuits and networks have not been described in detail so as not to unnecessarily obscure aspects of the embodiments. The embodiments can be combined, other embodiments can be utilized or structural and logical changes can be made without departing from the scope of the invention. The following detailed description is, therefore, not to be taken as a limiting sense.
[0019] In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one. In this document, the term “or” is used to refer to a nonexclusive “or,” such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated.

II. FIRST EXEMPLARY MEDICAL PRODUCT FOR DRESSING WOUNDS

[0020] FIG. 1 illustrates a medical product 100 for dressing wounds, in accordance with an embodiment. The medical product 100 includes a substrate 110 and an antimicrobial agent 108.
[0021] The substrate 110 includes a first part 102, an intermediate part 104 and a second part 106.
[0022] In an embodiment, the thickness of the intermediate part 104 is greater than the thickness of the first part 102.
[0023] In an embodiment, the thickness of the intermediate part 104 is greater than the thickness of the second part 106.
[0024] In an embodiment, the density of the intermediate part 104 is lesser than the density of the first part 102.
[0025] In an embodiment, the density of the intermediate part 104 is lesser than the density of the second part 106.
[0026] It shall be noted that relatively less density of the intermediate part 104 facilitates air circulation to the wound. As a result of air circulation, oxygen is supplied to the wounded tissues, thereby expediting the healing process.
[0027] In an embodiment, the thickness of the first part 102 is in the range of 2.4 Micron to 7.0 Micron (Yarn count range 20 Denier to 500 Denier).
[0028] In an embodiment, the thickness of the first part 102 is in the range of 2.5 Micron to 5.0 Micron (Yarn count range 100 Denier to 300 Denier).
[0029] In an embodiment, the density of the first part 102 is in the range of 20 Course per Inch to 60 Course per Inch, and 20 Wales per Inch to 60 Wales per Inch.
[0030] In an embodiment, the density of the first part 102 is in the range of 35 Course per Inch to 45 Course per Inch, and 35 Wales per Inch to 45 Wales per Inch.
[0031] In an embodiment, the thickness of the intermediate part 104 is in the range of 2 mm to 12 mm.
[0032] In an embodiment, the thickness of the intermediate part 104 is in the range of 2.2 mm to 3 mm.
[0033] In an embodiment, the density of the intermediate part 104 is in the range of 20 Piles Course per Inch to 70 Piles Course per Inch, and 30 Piles Wales per Inch to 50 Piles Wales per Inch.
[0034] In an embodiment, the density of the intermediate part 104 is in the range of 35 Piles Course per Inch to 45 Piles Course per Inch, and 35 Piles Wales per Inch to 45 Piles Wales per Inch.
[0035] In an embodiment, the thickness of the second part 106 is in the range of 2.4 Micron to 7.0 Micron (Yarn count range 20 Denier to 500 Denier).
[0036] In an embodiment, the thickness of the second part 106 is in the range of 2.5 Micron to 5.0 Micron (Yarn count range 100 Denier to 300 Denier).
[0037] In an embodiment, the density of the second part 106 is in the range of 20 Course per Inch to 60 Course per Inch, and 20 Wales per Inch to 60 Wales per Inch.
[0038] In an embodiment, the density of the second part 106 is in the range of 35 Course per Inch to 45 Course per Inch, and 35 Wales per Inch to 45 Wales per Inch.
[0039] In an embodiment, the substrate 110 is made using one or more material chosen from a group consisting of fibres, filaments, yarns and fabrics. Example of the material can include, but not limited to synthetic fibers, natural fibers, or combinations thereof. Synthetic fibers include, for example, polyester, acrylic, polyamide, polyolefin, polyaramid, polyurethane, regenerated cellulose, and blends thereof. Further, polyester includes, for example, poly acylonitriles, polyethylene terephthalate, polytriphenylene terephthalate, polybutylene terephthalate, polylactic acid, aramides, metaramides and combinations thereof. Polyamide includes, for example, nylon 6, nylon 6,6, and combinations thereof. Polyolefin includes, for example, polypropylene, polyethylene, and combinations thereof. Polyaramid includes, for example, poly-p-phenyleneteraphthalamid (Ex: Kevlar®), poly-m-phenyleneteraphthalamid (Ex: Nomex®), and combinations thereof. Natural fibers include, for example, wool, cotton, flax, rayon, jute, linen and blends thereof.
[0040] In an embodiment, the medical product 100 approximately comprises 80% to 95% Polyester (by weight), such as, for example, Polyethelne teraphtahlate, 5% to 20% Polyurethane by weight and 0.5% to 1% antimicrobial agent 108 by weight. In an embodiment, as per the required level of protections desired and depending on the area of use, the antimicrobial agent 108 can be up to 5 % on weight.
[0041] In an embodiment, a surface of the first part 102 is exposed to the atmosphere, whereas a surface of the second part 106 receives the antimicrobial agent 108, which is exposed to the skin/wound.
[0042] In an embodiment, the second part 106 and the intermediate part 104 receives the antimicrobial agent 108.
[0043] In an embodiment, the first part 102, the second part 106 and the intermediate part 104 receives the antimicrobial agent 108.
[0044] In an embodiment, the antimicrobial agent 108 is coated to the substrate 110.
[0045] It shall be noted that, even though the figures depict antimicrobial agent 108 as a layer provided over the second part 106, the antimicrobial agent 108 may be present in the first part 102 and the intermediate part 104, based on the configuration, as discussed earlier.
[0046] It shall be further note that, in an embodiment, the antimicrobial agent 108 present in the intermediate part 104 kills pathogens present in the exudate collected in the intermediate part 104
[0047] In an embodiment, the intermediate part 104 is between the first part 102 and the second part 106.
[0048] It shall be noted that the intermediate part 104 provides relatively greater thickness to the medical product 100, compared to conventional comparable medical products. Hence, one may interpret that the substrate 110 has a 3 dimensional mesh structure. Further, the relatively less dense and higher thickness intermediate part 104 enables air/oxygen circulation around the wound, thereby facilitating faster healing of the wound. Further, providing antimicrobial agent 108 in the intermediate part 104 facilitates killing of pathogens present in exudate that is exposed to the intermediate part 104. Furthermore, the antimicrobial agent 108 present in the intermediate part 104 can kill pathogens present in the atmospheres that can come in contact with the wound during air circulation, which is enabled by the medical product 100.
[0049] In an embodiment, a covalent bond is formed between the antimicrobial agent 108 and the substrate 110. This prevents leaching of the antimicrobial agent 108. The prevention of leaching limits evolution of superburgs. These superburgs, as discussed earlier are significantly resistant to silver particles or normal drugs that are meant to kill the pathogens.
[0050] In an embodiment, the antimicrobial agent 108 is a Quaternary Ammonium Salt (QAS). The QAS is 1-tetradecanaminium, N,N- dimethyl-N(3(trimethoxysilyl)propyl)chloride. The QAS kills the pathogens present in its vicinity, thereby limiting pathogen growth.

III. EXEMPLARY ILLUSTRATION OF FUNCTIONING OF QAS

[0051] FIG. 2 is an exemplary illustration of the QAS, in accordance with an embodiment. QAS bond by the silanol (a hydrolyzed silane) covalently bonds to the substrate 100 (chemisorption).This bonding is then made even more durable by the silanol functionality, which homopolymerises (bonds to its neighboring molecule). After the molecule has homopolymerised, it becomes an integral and permanent part of the product even on materials with which, it cannot react covalently. Silane Base antimicrobial anchored by covalent bonds. It allows for cross linking and homogenisation with other molecules.
[0052] It shall be noted that, QAS includes positively charged nitrogen, whereas the pathogens are negatively charged. The positively charged nitrogen attracts the negatively charged pathogens. FIG. 3a illustrates a pathogen being drawn towards the positively charged nitrogen, in accordance with an embodiment.
[0053] It shall be further noted that, the long molecular chain acts like sword that pierces the cell membrane of all pathogens that come in contact with it, thereby killing the pathogens. FIG. 3b illustrates rupturing the cell membrane of a pathogen, in accordance with an embodiment.
[0054] It is important to note that the aforementioned rupturing of the cell membrane of the pathogen is a physical process and not a chemical process. Hence, QAS is not consumed and does not dissipate. Therefore, antimicrobial active is not depleted and continues to control microbial growth. Hence, the medical product 100 can be used as a dressing for wounds for a relatively longer period of time, before it is replaced.

IV. EXEMPLARY ILLUSTRATION OF FUNCTIONING OF THE MEDICAL PRODUCT

[0055] FIG. 4 is an exemplary illustration of the medical product 100 applied over skin 404, in accordance with an embodiment. The medical product 100 is used to dress wound 406 present on the skin 404. The pathogen that may be present in the exudate is killed by the antimicrobial agent 108, as explained earlier.
[0056] Further, as illustrated, as a result of providing an intermediate layer 104 of relatively lesser density, air circulation is enabled. The circulation of air is illustrated by dotted lines 402. The circulation of air, as discussed earlier, facilitates faster healing of the wound 406.
[0057] Furthermore, any pathogens present in the air that may enter the medical product 100 are killed by the antimicrobial agent 108, as explained earlier. Hence, while air circulation is enabled, infection of wound by pathogens entering from external environment is prevented.

V. EXEMPLARY USE OF THE MEDICAL PRODUCT

[0058] The medical product 100 can be used for dressing several types of wound, such as, burns, graft and donor sites, venous leg ulcers and lymphedema, wounds being prepared for grafting, open wounds with moderate to heavy exudate, tunneling, trauma and open surgical wounds, wounds being treated with negative pressure wound therapy and diabetic foot ulcer, among others.
[0059] The medical product 100 is made to intimately contact the wound as a primary dressing material. The medical product 100 facilitates moving away of exudate from the wound towards the first part 102 of the medical product 100. A secondary dressing is provided over the medical product 100. The secondary dressing absorbs the exudate from the first part 102 of the medical product 100.
[0060] The secondary dressing material can be easily replaced without requiring specialized practitioner’s care. Antimicrobial agent 108 present in the medical product 100 provides effective protection against air borne microbes and also anaerobic microbes present in the wound exude. This assists in the wound curing process and reduces the discomfort associated with the wound.
[0061] Further, the effectiveness is tested using United States Pharmacopeia Antimicrobial Effectiveness Test (USP 51). This study is done to check the ability of the antimicrobial agent i.e. 1-Tetradecanaminium, N, N-dimethyl-N-[3-(trimethoxysilyl)propyl] used in the medical product 100 to kill or prevent the growth of pathogens at least for seven days. Antimicrobial study was carried out in five different pathogens which is shown in the table below:

Column 1 Column 2 Column 3 Column 4 Column 5
Antimicrobial effectiveness test Inoculum concentration (CFU’s/mL)Results
Test organism Day 1 Day 7 Day14 Day 28
P.aeruginosa 2.00 x 107 100.00% 100.00% 100.00%
E. coli 3.00 x 107 100.00% 100.00% 100.00%
S. aureus 11.00 x 106 100.00% 100.00% 100.00%
Candida albicans 2.00 x 106 99.99% 99.99% 99.99%
Aspergillus Niger 1.00 x 106 100.00% 100.00% 100.00%

[0062] In the above table, column 1 refers to different micro organism and column 2 refers to the concentration of the inoculum taken for the study.
[0063] After incubating the inoculated test product for seven days, it was observed that all the test microorganisms were killed as mentioned in the above table. In other words, the above table can be interpreted to mean that a wound can be theoretically left unattended with dressing done using medical product 100 for 28 days, depending on the wound type, without risk of infections. This provides comfort for the patients to do away with daily dressing changes.

VI. CONCLUSION
[0064] In light of the foregoing description, a person skilled in the art will appreciate the advantages of the embodiments, some of which are mentioned below.
[0065] The medical product 100 of the embodiments avoids contamination of wound by external pathogens.
[0066] The medical product 100 of the embodiments kills pathogens present in the exudate, thereby preventing infection for relatively longer period of time.
[0067] The medical product 100 of the embodiments, as a result of the intermediate layer 104 facilitates the soaking away of the exudate from the wound.
[0068] The medical product 100 of the embodiments, as a result of the intermediate layer 104, which is relatively less dense, enables air circulation around the wound, thereby facilitating faster healing of the wound.
[0069] The medical product 100 of the embodiments kills the pathogen by way of mechanical action and not by leaching, thereby avoiding chemical interference with the wound. Hence, the medical product 100 is relatively safer.
[0070] The medical product 100 of the embodiments, as a result of having non-leaching property, does not give chance for the pathogens to be drug resistant, thereby avoiding creation of super burgs.
[0071] The medical product 100 of the embodiments passes the USP 51 barrier study for not allowing growth of pathogens till 28 days. In other words, the wound can be theoretically left unattended, with this medical product 100 being used for dressing, for 28 days, depending on the wound type without any risk of infections.
[0072] It shall be noted that some of the processes described above are described as sequence of steps, this was done solely for the sake of illustration. Accordingly, it is contemplated that some steps may be added, some steps may be omitted, the order of the steps may be re-arranged, or some steps may be performed simultaneously.
[0073] Although embodiments have been described with reference to specific example embodiments, it will be evident that various modifications and changes may be made to these embodiments without departing from the broader spirit and scope of the system and method described herein. Accordingly, the specification and drawings are to be regarded in an illustrative rather than a restrictive sense.
[0074] Many alterations and modifications of the present invention will no doubt become apparent to a person of ordinary skill in the art after having read the foregoing description. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. It is to be understood that the description above contains many specifications, these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the personally preferred embodiments of this invention. Thus the scope of the invention should be determined by the appended claims and their legal equivalents rather than by the examples given.
CLAIMS
We claim:
1. A medical product for dressing wounds, the medical product comprising:
a substrate comprising a first part, a second part and an intermediate part, wherein the intermediate part is in between the first part and the second part, wherein the density of the intermediate part is lesser than the density of the first part and the second part; and
an antimicrobial agent, wherein the antimicrobial agent is Quaternary Ammonium Salt, wherein the antimicrobial agent is received by the substrate, thereby exposing the antimicrobial agent to an wound dressed using the medical product.
2. The medical product according to claim 1, wherein the antimicrobial agent is covalently bonded to the substrate.
3. The medical product according to claim 2, wherein the antimicrobial agent is covalently bonded to at least the second part and the intermediate part of the substrate.
4. The medical product according to claim 1, wherein the antimicrobial agent is 1-Tetradecanaminium, N,N-dimethyl-N-[3-(trimethoxysilyl)propyl]-, chloride.
5. The medical product according to claim 1, wherein the density of the first part is in the range of 20 Course per Inch to 60 Course per Inch, and 20 Wales per Inch to 60 Wales per Inch.
6. The medical product according to claim 1, wherein the thickness of the first part is in the range of 2.4 Micron to 7.0 Micron.
7. The medical product according to claim 1, wherein the density of the second part is in the range of 20 Course per Inch to 60 Course per Inch, and 20 Wales per Inch to 60 Wales per Inch.
8. The medical product according to claim 1, wherein the thickness of the second part is in the range of 2.4 micron to 7.0 micron.
9. The medical product according to claim 1, wherein the density of the intermediate part is in the range of 20 Piles Course per Inch to 70 Piles Course per Inch, and 30 Piles Wales per Inch to 50 Piles Wales per Inch.
10. The medical product according to claim 1, wherein the thickness of the intermediate part is in the range of 2 mm to 12 mm.
11. The medical product according to claim 1, wherein the substrate is made using a material comprising Polyethelne Teraphtahlate.
12. The medical product according to claim 1, wherein the substrate is made using a material comprising Polyethelne Teraphtahlate and Polyurethane.
13. The medical product according to claim 1, wherein the substrate is made using one or combination of material selected from a group consisting of fibre, filament, yarn, fabric, synthetic fiber, natural fiber, polyester, acrylic, polyamide, polyolefin, polyaramid, polyurethane, regenerated cellulose, poly acylonitriles, polytriphenylene terephthalate, polybutylene terephthalate, polylactic acid, aramides, metaramides, nylon 6, nylon 6,6, polypropylene, polyethylene, poly-p-phenyleneteraphthalamid, poly-m-phenyleneteraphthalamid, wool, cotton, flax, rayon, jute and linen.
14. The medical product according to claim 1, wherein the medical product comprises 80% to 90% Polyethelne Teraphtahlate by weight, 5% to 20% Polyurethane by weight and 0.5% to 1% antimicrobial agent by weight.
15. A medical product as herein above described in the specification with reference to figures.
ABSTRACT
A medical product (100) for dressing wounds is provided. The medical product (100) includes a substrate (110). The substrate (110) includes a first part (102), a second part (106) and an intermediate part (104), wherein the intermediate part (104) is in between the first part (102) and the second part (106). The density of the intermediate part (104) is lesser than the density of the first part (102) and the second part (106). Further, the medical product (100) includes an antimicrobial agent (108). The antimicrobial agent (108) is Quaternary Ammonium Salt, wherein the antimicrobial agent (108) is received by the substrate (110), thereby exposing the antimicrobial agent to an wound (406) dressed using the medical product (100).
Reference figure: FIG. 4